# Biomarkers of Anti-TNF Treatment in Inflammatory Bowel Disease (IBD)

> **NCT01971970** · — · COMPLETED · sponsor: **Erasmus Medical Center** · enrollment: 45 (actual)

## Conditions studied

- Inflammatory Bowel Diseases

## Interventions

- **BIOLOGICAL:** Infliximab
- **BIOLOGICAL:** Adalimumab

## Key facts

- **NCT ID:** NCT01971970
- **Lead sponsor:** Erasmus Medical Center
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2013-10
- **Primary completion:** 2016-10-30
- **Final completion:** 2017-01-30
- **Target enrollment:** 45 (ACTUAL)
- **Last updated:** 2022-01-27

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01971970

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01971970, "Biomarkers of Anti-TNF Treatment in Inflammatory Bowel Disease (IBD)". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01971970. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*